Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
May 22, 2026
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
May 22, 2026
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
May 21, 2026
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
May 21, 2026
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 13, 2026